Unger, Lukas W.
Forstner, Bernadette
Schneglberger, Stephan
Muckenhuber, Moritz
Eigenbauer, Ernst
Scheiner, Bernhard
Mandorfer, Mattias
Trauner, Michael
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 22 November 2018
Accepted: 13 August 2019
First Online: 6 September 2019
Conflict of interest
: L.W. Unger, B. Forstner, S. Schneglberger, M. Muckenhuber, E. Eigenbauer, and B. Scheiner, declare that they have no competing interests. M. Mandorfer has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, W. L. Gore & Associates, and Janssen. M. Trauner has served as speaker for BMS, Falk Foundation, Gilead and MSD; advisory boards for Albireo, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex and Regulus. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. He is also coinventor of patents on the medical use of norUDCA filed by the Medical University of Graz. T. Reiberger has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, W. L. Gore & Associates, and MSD and has received research funding from AbbVie, Boehringer Ingelheim, Gilead, MSD, Phenex Pharmaceuticals, and Philips.